Search results
Results From The WOW.Com Content Network
Vasopressin. Human vasopressin, also called antidiuretic hormone (ADH), arginine vasopressin (AVP) or argipressin, [5] is a hormone synthesized from the AVP gene as a peptide prohormone in neurons in the hypothalamus, [6] and is converted to AVP. It then travels down the axon terminating in the posterior pituitary, and is released from vesicles ...
Vasopressin agonists are used therapeutically in various conditions, and its long-acting synthetic analogue desmopressin is used in conditions featuring low vasopressin secretion, as well as for control of bleeding (in some forms of von Willebrand disease and in mild haemophilia A) and in extreme cases of bedwetting by children.
Demeclocycline (INN, BAN, USAN, brand name Declomycin) is a tetracycline antibiotic which was derived from a mutant strain of Streptomyces aureofaciens. [1][2]
Antibiotic candidates Generic name Origin Susceptible phyla Stage of development Mechanism of action Unclassified Teixobactin: Eleftheria terrae: Gram-positive, including antibiotic resistant S. aureus and M. tuberculosis: No human trials scheduled: Binds fatty acid precursors to cell wall Malacidins: Uncultured Bacterium
The "vaptan" drugs act by directly blocking the action of vasopressin at its receptors (V 1A, V 1B and V 2).These receptors have a variety of functions, with the V 1A and V 2 receptors are expressed peripherally and involved in the modulation of blood pressure and kidney function respectively, while the V 1A and V 1B receptors are expressed in the central nervous system.
Vasopressin receptor antagonists (VRAs) are drugs that block vasopressin receptors. Most commonly VRAs are used to treat hyponatremia caused by syndrome of inappropriate antidiuretic hormone secretion (SIADH), congestive heart failure (CHF) and cirrhosis. [2] Somatostatin is a competitive inhibitor.
Conivaptan. Conivaptan, sold under the brand name Vaprisol, is a non-peptide inhibitor of the receptor for anti-diuretic hormone, also called vasopressin. It was approved in 2004 for hyponatremia (low blood sodium levels). The compound was discovered by Astellas and marked in 2006. The drug is now marketed by Cumberland Pharmaceuticals, Inc.
This is a list of common β-lactam antibiotics—both administered drugs and those not in clinical use—organized by structural class. Antibiotics are listed alphabetically within their class or subclass by their nonproprietary name. If an antibiotic is a combination drug, both ingredients will be listed.